IQVIA Holdings Inc. (NYSE:IQV) Receives $229.86 Average Price Target from Brokerages

Shares of IQVIA Holdings Inc. (NYSE:IQV) have earned an average recommendation of “Moderate Buy” from the twenty-four research firms that are currently covering the firm, Marketbeat reports. Six investment analysts have rated the stock with a hold recommendation and eighteen have assigned a buy recommendation to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $229.6364.

A number of brokerages have recently issued reports on IQV. Mizuho upped their price objective on shares of IQVIA from $190.00 to $225.00 and gave the company an “outperform” rating in a research note on Friday, July 25th. Robert W. Baird upped their price objective on shares of IQVIA from $159.00 to $196.00 and gave the company a “neutral” rating in a research note on Wednesday, July 23rd. Evercore ISI upped their price objective on shares of IQVIA from $170.00 to $180.00 and gave the company an “outperform” rating in a research note on Wednesday, July 9th. William Blair reaffirmed an “outperform” rating on shares of IQVIA in a research note on Wednesday, July 23rd. Finally, Barclays upped their price objective on shares of IQVIA from $165.00 to $185.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 23rd.

Insider Buying and Selling at IQVIA

In other IQVIA news, insider Eric Sherbet sold 5,800 shares of the stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the completion of the sale, the insider owned 27,178 shares of the company’s stock, valued at $5,165,178.90. This represents a 17.59% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Keriann Cherofsky sold 549 shares of the stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $191.53, for a total transaction of $105,149.97. Following the sale, the insider directly owned 2,910 shares of the company’s stock, valued at $557,352.30. The trade was a 15.87% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 1.60% of the company’s stock.

Institutional Investors Weigh In On IQVIA

Several institutional investors have recently added to or reduced their stakes in the company. Osaic Holdings Inc. boosted its position in IQVIA by 32.0% during the 2nd quarter. Osaic Holdings Inc. now owns 71,103 shares of the medical research company’s stock valued at $11,233,000 after buying an additional 17,217 shares during the period. Orion Porfolio Solutions LLC raised its holdings in IQVIA by 7.0% in the 2nd quarter. Orion Porfolio Solutions LLC now owns 19,552 shares of the medical research company’s stock worth $3,081,000 after purchasing an additional 1,282 shares in the last quarter. B. Riley Wealth Advisors Inc. bought a new position in IQVIA in the 2nd quarter worth $242,000. Cape Investment Advisory Inc. raised its holdings in IQVIA by 34.0% in the 2nd quarter. Cape Investment Advisory Inc. now owns 10,710 shares of the medical research company’s stock worth $1,688,000 after purchasing an additional 2,719 shares in the last quarter. Finally, Advisory Services Network LLC raised its holdings in IQVIA by 49.3% in the 2nd quarter. Advisory Services Network LLC now owns 5,836 shares of the medical research company’s stock worth $920,000 after purchasing an additional 1,927 shares in the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Price Performance

IQV stock opened at $187.34 on Monday. The company has a debt-to-equity ratio of 2.45, a current ratio of 0.84 and a quick ratio of 0.84. IQVIA has a one year low of $134.65 and a one year high of $248.03. The stock has a market cap of $31.85 billion, a PE ratio of 27.11, a P/E/G ratio of 2.06 and a beta of 1.32. The firm has a 50 day simple moving average of $182.40 and a two-hundred day simple moving average of $167.12.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.77 by $0.04. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The company had revenue of $4.02 billion during the quarter, compared to analysts’ expectations of $3.96 billion. During the same quarter in the prior year, the company earned $2.64 EPS. The firm’s revenue was up 5.3% on a year-over-year basis. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. On average, analysts predict that IQVIA will post 10.84 EPS for the current fiscal year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.